MOESM1 of Carvacrol ameliorates acute campylobacteriosis in a clinical murine infection model

Additional file 1: Figure S1. Kinetic survey of clinical conditions following carvacrol treatment of C. jejuni infected mice. Starting 4 days prior peroral C. jejuni infection on day (d) 0 and d1, secondary abiotic IL-10−/− mice were treated with synthetic carvacrol (CARVA; white boxes) or placebo (PLC; grey boxes) via the drinking water. Severities of clinical symptoms were surveyed daily from d0 until d6 applying a standardized clinical scoring system postinfection (see “Methods”). Box plots represent the 75th and 25th percentiles of medians (black bar inside the boxes). Total range, significance levels (p-values; determined between groups at respective time points; ***p < 0.001) by the Mann–Whitney U test and numbers of analyzed animals (in parentheses) are indicated. Data were pooled from four independent experiments.